Humane Genomics

Humane Genomics is pioneering a novel approach to cancer treatment through the development of engineered oncolytic viruses. Their platform focuses on creating cancer-killing viruses designed with a first-principles methodology. By utilizing a highly lytic RNA virus incorporating a "two-factor authentication" mechanism—selective infection combined with selective replication—Humane Genomics achieves a significantly improved on-target to off-target kill ratio, exceeding 1000:1. The company's initial focus is on pediatric liver cancer (hepatoblastoma), a challenging disease, in collaboration with leading experts at Texas Children's Hospital. Preclinical in vivo data from mouse models demonstrates the safety of their approach. Current research is focused on generating efficacy data, with preliminary results indicating a 50% reduction in tumor volume.